| Gary Bremen, DO | |
|
1601 Nw 114th St, Clive, IA 50325-7007 | |
| (515) 222-7000 | |
| (515) 222-7037 |
| Full Name | Gary Bremen |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 44 Years |
| Location | 1601 Nw 114th St, Clive, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689781676 | NPI | - | NPPES |
| 55202 | Other | IA | WELLMARK |
| 065788 | Other | IA | HEALTH ALLIANCE |
| 1027748 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 01857 (Iowa) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Clinics Inc | 7911810882 | 373 |
News Archive
Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).
The trillions of bacteria in the human gut affect our health in multiple ways including effects on immune functions and metabolism.
"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, on Wednesday announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports.
To honor nurses for their commitment to high-quality healthcare delivery and to commemorate upcoming National Nurses Week, WGU Washington has announced the WGU Washington Loves Nurses Scholarship. During the week of May 6, the state-endorsed, nonprofit university will award up to $20,000 in scholarships to motivated nurses who wish to pursue a bachelor's or master's degree in its College of Health Professions.
AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.
› Verified 8 days ago
| Entity Name | Mercy Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457691941 PECOS PAC ID: 7911810882 Enrollment ID: O20031112000238 |
News Archive
Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).
The trillions of bacteria in the human gut affect our health in multiple ways including effects on immune functions and metabolism.
"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, on Wednesday announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports.
To honor nurses for their commitment to high-quality healthcare delivery and to commemorate upcoming National Nurses Week, WGU Washington has announced the WGU Washington Loves Nurses Scholarship. During the week of May 6, the state-endorsed, nonprofit university will award up to $20,000 in scholarships to motivated nurses who wish to pursue a bachelor's or master's degree in its College of Health Professions.
AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gary Bremen, DO Po Box 1475, Des Moines, IA 50305-1475 Ph: (515) 222-7000 | Gary Bremen, DO 1601 Nw 114th St, Clive, IA 50325-7007 Ph: (515) 222-7000 |
News Archive
Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).
The trillions of bacteria in the human gut affect our health in multiple ways including effects on immune functions and metabolism.
"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, on Wednesday announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports.
To honor nurses for their commitment to high-quality healthcare delivery and to commemorate upcoming National Nurses Week, WGU Washington has announced the WGU Washington Loves Nurses Scholarship. During the week of May 6, the state-endorsed, nonprofit university will award up to $20,000 in scholarships to motivated nurses who wish to pursue a bachelor's or master's degree in its College of Health Professions.
AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.
› Verified 8 days ago
Stephen Eckstat, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 1601 Nw 114th St, Clive, IA 50325 Phone: 515-222-7000 Fax: 515-222-7037 | |
Dr. Daniel Charles Miller, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 12871 University Ave, Suite 130, Clive, IA 50325 Phone: 515-222-4419 Fax: 515-222-6965 | |
Randall Miller, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1601 Nw 114th St, Clive, IA 50325 Phone: 515-222-7000 Fax: 515-222-2737 | |
Lon Russell Brewer, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1924 Nw 88th Ct, Clive, IA 50325 Phone: 515-237-3974 Fax: 515-883-2692 | |
Erin Netteland-sandvig, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1601 Nw 114th St, Clive, IA 50325 Phone: 515-222-7000 Fax: 515-222-7037 | |
Robert D Conner, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 13435 University Ave, Suite 500, Clive, IA 50325 Phone: 515-255-7132 Fax: 515-218-1500 | |
Dr. Steven J. Humphrey, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 14961 Woodcreek Ln, Clive, IA 50325 Phone: 515-865-4501 |